![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
Molecular Pharmacology, Vol 12, 800-812, Copyright © 1976 by the American Society for Pharmacology and Experimental Therapeutics
1 Departments of Pharmacology and Experimental Therapeutics and of Psychiatry and Behavioral Sciences,
The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205
[3H]Haloperidol and [3H]dopamine bind in saturable fashion to membranes from calf brain with high affinity and other characteristics indicating an association with post-synaptic dopamine receptors. Kinetic analysis of rates of association and dissociation yields KD values in agreement with equilibrium measurements. Regional variations in [3H]dopamine and [3H]haloperidol binding are parallel and correspond to regional differences in dopaminergic innervation. Drug specificity does not appear to differ between limbic and striatal areas. The relative potencies of various agonists and antagonists on the binding of the two ligands parallel their pharmacological actions at dopamine receptor sites. Dopamine agonists have 6-38 times more affinity for [3H]dopamine than [3H]haloperidol binding sites. By contrast, dopamine antagonists have 20-12,000 times more affinity for [3H]haloperidol than [3H]dopamine binding sites. Ergot derivatives, including d-lysergic acid diethylamide, and other serotonin antagonists have substantial affinity for both types of binding.
Note:
ACKNOWLEDGMENT
We thank Janet Ryan for excellent technical assistance.
This article has been cited by other articles:
|
|
 |
|
  J. M. Stone, P. D. Morrison, and L. S. Pilowsky Review: Glutamate and dopamine dysregulation in schizophrenia a synthesis and selective review J Psychopharmacol, June 1, 2007; 21(4): 440 - 452. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Y. S. Kalani, N. Vaidehi, S. E. Hall, R. J. Trabanino, P. L. Freddolino, M. A. Kalani, W. B. Floriano, V. W. T. Kam, and W. A. Goddard III The predicted 3D structure of the human D2 dopamine receptor and the binding site and binding affinities for agonists and antagonists PNAS, March 16, 2004; 101(11): 3815 - 3820. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Seeman and S. Kapur Schizophrenia: More dopamine, more D2 receptors PNAS, July 5, 2000; 97(14): 7673 - 7675. [Full Text] [PDF]
|
|
|
|
 |
|
 D Lozovsky, C. Saller, and I. Kopin Dopamine receptor binding is increased in diabetic rats Science, November 27, 1981; 214(4524): 1031 - 1033. [Abstract] [PDF]
|
|
|
|
|
|
O. Steinsland and J. Hieble Dopaminergic inhibition of adrenergic neurotransmission as a model for studies on dopamine receptor mechanisms Science, January 27, 1978; 199(4327): 443 - 445. [Abstract] [PDF]
|
|
|
|
|
|
D. U'Prichard, D. Greenberg, P. Sheehan, and S. Snyder Tricyclic antidepressants: therapeutic properties and affinity for alpha-noradrenergic receptor binding sites in the brain Science, January 13, 1978; 199(4325): 197 - 198. [Abstract] [PDF]
|
|
|
|
|
|
I Creese, D. Burt, and S. Snyder Dopamine receptor binding enhancement accompanies lesion-induced behavioral supersensitivity Science, August 5, 1977; 197(4303): 596 - 598. [Abstract] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
